| Literature DB >> 32318061 |
Yaw Aniweh1, Prince B Nyarko1,2, Essel Charles-Chess1,2, Felix Ansah1,2, Faith H A Osier3,4,5,6, Evelyn Quansah1,2, Laty Gaye Thiam1,2, Gathoni Kamuyu7, Kevin Marsh3,6,8, David J Conway9, Kevin K A Tetteh9, Gordon A Awandare1,2.
Abstract
Understanding the functional role of proteins expressed by Plasmodium falciparum is an important step toward unlocking potential targets for the development of therapeutic or diagnostic interventions. The armadillo (ARM) repeat protein superfamily is associated with varied functions across the eukaryotes. Therefore, it is important to understand the role of members of this protein family in Plasmodium biology. The Plasmodium falciparum armadillo repeats only (PfARO; Pf3D7_0414900) and P. falciparum merozoite organizing proteins (PfMOP; Pf3D7_0917000) are armadillo-repeat containing proteins previously characterized in P. falciparum. Here, we describe the characterization of another ARM repeat-containing protein in P. falciparum, which we have named the P. falciparum Merozoites-Associated Armadillo repeats protein (PfMAAP). Antibodies raised to three different synthetic peptides of PfMAAP show apical staining of free merozoites and those within the mature infected schizont. We also demonstrate that the antibodies raised to the PfMAAP peptides inhibited invasion of erythrocytes by merozoites from different parasite isolates. In addition, naturally acquired human antibodies to the N- and C- termini of PfMAAP are associated with a reduced risk of malaria in a prospective cohort analysis.Entities:
Keywords: Malaria; antibodies; antigen; armadillo; invasion; merozoites; recombinant protein
Mesh:
Substances:
Year: 2020 PMID: 32318061 PMCID: PMC7155890 DOI: 10.3389/fimmu.2020.00505
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Summary of PfMAAP protein characteristics, including location of peptides and recombinants and transcript expression levels. (A) Cartoon of the PfMAAP protein highlighting the location of the PfMAAP peptides, shown with black lines above the scheme and labeled 1, 2, and 3. The position of the Escherichia coli expressed conserved N- and C-termini and central repeat region are shown below the scheme, with black lines and corresponding amino acid positions. The Armadillo repeat region (orange, amino acid position corresponds to central repeat region) and the Pumilio homolog domain (red line, with amino acid positions shown). (B) The predicted structural model for PfMAAP is shown as a ribbon diagram preceded by other known armadillo repeat containing proteins, Sys-1 (symmetrical sisters-1, 3C2H in Protein Data Bank), Plakophilin-1 (1XM9) and B-catenin (1JDH), highlighting the structural similarity between PfMAAP and other armadillo repeat containing proteins. (C) Boxplots showing differential expression of PfMAAP across the asexual stage of development for four laboratory isolates and one clinical isolate. Transcript fold change is plotted against time (hours post invasion), with peak expression at 40 or 48 h post merozoites invasion. Transcript experiments were conducted in triplicate and conducted on two independent occasions.
Figure 2Localization of PfMAAP in schizonts and merozoites. (A) Co-localization of anti-PfMAAP peptide antibody reactivities (green) with the apical markers PfAMA1 (microneme, red), PfRAP2 (rhoptry bulb, red) PfRON4 (rhoptry neck, red). Staining shows clear punctate apical staining for all three apical markers; (B) anti-PfMAAP (red) co-localization with inner membrane complex (IMC) protein GAP45 and the merozoite surface markers PfMSP1 (green). (C) The localization of anti-PfMAAP antibody reactivities (green) in free merozoites relative to PfAMA1, PfRAP2, and PfRON4. (D) Percentage (%) representation of the different staining patterns observed in the schizont stage (n = 500) as either MSP-like or any other pattern and in merozoites (n = 500) as either punctate apical localization or diffuse was performed using FIJI Image J. DAPI staining of the nuclei is shown in blue and the images are shown in the final column (merge). Fifty images were taken per antibody tested using an Olympus model BX41 fluorescent microscope with a x100 oil-immersion objective.
Figure 3PfMAAP is expressed in multiple P. falciparum strains. (A) PfMAAP1 detection of the protein in Western blot from 3D7, W2mef, and Dd2 schizont extracts. Molecular weight (kDa) indicated by the side. Molecular weight (kDa) indicated by the side.
Figure 4PfMAAP antibodies inhibit merozoites invasion. Evaluation of the PfMAAP polyclonal antibodies in a dose-dependent manner for (A) Dd2 (B) 3D7 and (C) W2mef parasite isolates. The antibody reactivity for each is shown, PfMAAP1 (red line), 2 (green line) and 3 (purple line), with the pre-immune negative control shown in blue. Percentage (%) invasion inhibition is plotted on the y-axis with the antibody concentrations (μg/ml) plotted on the x-axis. Pre-immunization antibodies were used as the negative control. All the assays were conducted in triplicate as two separate experiments with the plots displayed as n ± sem.
Figure 5PfMAAP antibodies are associated with naturally acquired immunity. (A) SDS PAGE showing the purified expressed and purified GST-tagged PfMAAP protein regions; N-term-GST, Central Repeat-GST, and C-term-GST. Antibody responses (OD) across all ages (October 2000) to the truncated PfMAAP recombinant antigens in (B) Chonyi (n = 518). Age categories are as follows: 1 = 1–2 year, n = 54; 2 = 3–4 year, n = 55; 3 = 5–6 year, n = 55; 4 = 7–8 year, n = 59; 5 = 9–10 year, n = 59; 6 = 11–15, n = 96; 7 = 16–30 n = 57; 8 = 31–50, n = 56; and 9 = 51–82, n = 27.
Association between the presence of serum IgG to the panel of 3 antigens in children aged <11 years and parasite slide positive in October 2000 in the Chonyi village, and the occurrence of malaria over the following 6 months.
| N-term | 18% | 41% | 0.44 | 0.47 (0.25–0.89) | |
| Repeat | 20% | 43% | 0.48 | 0.58 (0.31–1.04) | 0.068 |
| C-term | 20% | 41% | 0.49 | 0.52 (0.28–0.93) | |
CI, Confidence Interval; IRR, Incidence Risk Ratio.
Number of individuals developing malaria/the total number of individuals that were IgG positive or negative.
The incidence Risk Ratio was estimated from multivariate analysis after adjusting for age and reactivity to Plasmodium falciparum schizont extract in a generalized linear models.
Analysis focused on individuals who were parasitaemic at the time of serum sampling in October 2000.
P < 0.05.